Stem cell therapy shows promise for common cause of blindnessNovember 14, 2017
New Orleans - Nov. 14, 2017 -- Results from two early clinical trials show that it may be possible to use human embryonic stem cells as treatment for the dry form of macular degeneration, according to presentations given today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients' vision.
In both studies, researchers turned embryonic stem cells into a type of retinal support cell, called retinal pigment epithelial (RPE) cells, and injected them into the eyes of people suffering from dry age-related macular degeneration (AMD), a leading cause of new blindness in people over age 55. There is currently no treatment available for this disease affecting 30 million people worldwide, though nutritional supplements can be protective.
In a healthy retina, RPE cells provide supportive functions such as nutrition and waste management for photoreceptors, the cells that process light, allowing us to see. Dysfunction and degeneration of RPE cells are part of the process that leads to visual loss in age-related macular degeneration. The human embryonic stem cell-derived RPE cells injected under the retina are designed to support and/or replace the patient's failing RPE cells.
Experts in regenerative medicine believe that macular degeneration will be one of the first areas of success with stem-cell therapy. This is because it is relatively easy to grow large numbers of RPE cells in the lab. These cells are nearly identical to those in the eye. RPE cells do not require formation of neuronal connections to support the photoreceptors within the retina. Also, the location in the eye in which the cells are transplanted is recognized as an immune-privileged site, meaning it's one of the very few sites in the body in which the risk of rejection of the transplanted cells is low. Lastly, the treatment can be accomplished with a small number of cells in a very localized area, reducing the risks.
The researchers from Hadassah-Hebrew University Medical Center in Jerusalem, Israel, conducted studies designed to test the safety of the procedure in human subjects. They injected a suspension of either 50,000 or 200,000 RPE cells derived from human embryonic stem cells underneath the patients' retina. The surgical procedure was well-tolerated. Within a few weeks, they could see signs that the retina was healing at the injection site, and images of the back of the eye suggest the possibility that the transplanted RPE cells survived. Patients' vision remained largely stable throughout the study, and they suffered no unexpected side effects.
"We're encouraged by the results thus far," said Eyal Banin, M.D., Ph.D., lead investigator and one of the developers of the technology. "But this is just a first step in the long road towards making regenerative cell therapy a reality in macular and retinal degeneration."
An additional trial site for this stem cell treatment is expected to open soon in the United States.
A second research group from Bascom Palmer Eye Institute in Miami has conducted two studies using RPE cells derived from human embryonic stem cells to treat patients with dry AMD, as well as patients with a different form of retinal degeneration called Stargardt disease. It's the most common form of inherited juvenile AMD. Like dry AMD, there is no treatment available for this blinding disease.
Stem cells implanted in these patients survived for up to three years, and there were no side effects. Some of these patients even gained vision.
"RPE cells appear to be well tolerated in the human eyes," said lead researcher Ninel Z. Gregori M.D., of Bascom Palmer Eye Institute. "There were no serious adverse events attributable to the transplanted RPE cells, including no tumor formation. "This study supports further development of human embryonic stem cell-derived RPE for degenerative diseases of the macula."
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.
American Academy of Ophthalmology
Related Macular Degeneration Articles:
Age-related macular degeneration (AMD) is a major cause of severe visual impairment in older populations and is characterized by progressive destruction of the retinal pigment epithelial cells and photoreceptors due to low-grade inflammation, ischemia and oxidative stress.
Using an animal model of Best disease in combination with biochemical and optical assays, a team of researchers at the University of Pennsylvania has pinpointed a number of abnormalities that give rise to the impairments seen in the blinding disease.
Highly effective current treatments for vision loss need to be allied with careful counselling to ensure patients maintain good psychological health as well as good vision, new research recommends.
Age-related macular degeneration (AMD), the leading cause of vision loss among older adults in the United States, is often associated with psychological stress.
Two gene mutations that trigger a retinal disease that causes blindness in one in 5,000 males have been mapped, leading to the potential for new therapeutic treatments.
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision loss in people over 55.
In a study published this week in the Proceedings of the National Academy of Sciences, a University of Wisconsin-Madison research team pinpoints how immune abnormalities beneath the retina result in macular degeneration, a common condition that often causes blindness.
BrightFocus Foundation today recognized five scientists in the fields of macular degeneration and glaucoma research, awarding them grants named in honor of leaders in vision research and advocacy.
In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye.
For the first time, researchers at LSU Health New Orleans have shown that a protein critical to the body's ability to remove waste products from the brain and retina is diminished in age-related macular degeneration, after first making the discovery in an Alzheimer's disease brain.
Related Macular Degeneration Reading:
Macular Degeneration: A Complete Guide for Patients and Their Families
by Michael A. Samuel (Author)
In this newly revised and updated second edition patients and their loved ones can turn to one easy-to-understand and authoritative source for up-to-date information about macular degeneration. A wealth of insights into what the disease is and the array of contemporary treatment options. View Details
Macular Degeneration: The Complete Guide to Saving and Maximizing Your Sight
by Lylas G. Mogk (Author), Marja Mogk (Author)
The acclaimed book on macular degeneration—now completely revised and updated with cutting edge research and the latest developments in the field.
More than fifteen million Americans have age-related macular degeneration (AMD), and the disease will strike 200,000 more people this year. It is the most prevalent cause of vision loss in the western world. Dr. Lylas Mogk, the founding director of the Visual Rehabilitation and Research Center of the Henry Ford Health System, has a unique professional and personal understanding of AMD. A doctor and loving daughter of a parent with... View Details
How I Beat Macular Degeneration in the Early Stages and How You Can, Too!: Your guide to improving your vision, higher energy levels, and longer life
by Alan N McClain (Author)
A NEW TOTAL HEALTH PROGRAM FOR AGES 18 AND UP - empowering you to - Build energy & career success - improve vision - many proven health tips - Developed for career success in the exciting computer & aviation industries - Further improved to enable those over 50 to avoid and overcome a worldwide eye epidemic currently affecting one in three people over the age of 65 - blurred vision that prevents reading, driving, and recognizing faces.
Learn how you can turn back the early stages of macular degeneration with a daily regimen of healthy foods, exercise and quality rest,... View Details
Eat Right for Your Sight: Simple, Tasty Recipes that Help Reduce the Risk of Vision Loss from Macular Degeneration
by Jennifer Trainer Thompson (Author), Johanna M. Seddon MD ScM (Author), The American Macular Degeneration Foundation (Draft Writer)
Safeguard your vision with 85 simple, satisfying recipes rich in the nutrients that fight macular degeneration
The Bad News: Age-related macular degeneration (AMD) is the leading cause of central vision loss in adults over the age of fifty. It can wreak havoc on the ability to see faces, read, drive, and move about safely. Millions of people are at risk, and we still don’t have a cure.
The Good News: The latest research suggests that healthy lifestyle choices, including a diet rich in lutein, zeaxanthin, and other key nutrients, can delay the onset... View Details
What You Must Know About Age-Related Macular Degeneration: How You Can Prevent, Stop, or Reverse AMD
by Jeffrey Anshel OD (Author), Laura Stevens M.Sci (Author)
Age-related macular degeneration―AMD―is the most commonly diagnosed eye disorder in people over fifty. Well over two million Americans have been told they have AMD, and that number is expected to grow substantially. While this is a frightening statistic, over the last several years, medical researchers have shown that a number of effective treatments can slow, stop, and even reverse the progress of AMD. Now, best-selling authors Dr. Jeffrey Anshel and Laura Stevens, who herself has been diagnosed with this condition, have joined forces to produce an up-to-date guide to what you need to... View Details
Overcoming Macular Degeneration: A Guide to Seeing Beyond the Clouds
by J.D. Solomon (Contributor)
Each year, more than 400,000 Americans are diagnosed with macular degeneration, an age-related, progressive eye disease that immediately raises a fear of total blindness. The good news is: YOU ARE NOT GOING BLIND. However, you are dealing with a disease that causes serious visual impairment—an inconvenience the author, Dr. Yale Solomon, is personally familiar with because he has macular degeneration. Now this respected ophthalmologist offers a compassionate and understanding look at both the medical and human side of macular degeneration and ways to meet the challenge of its impact on... View Details
Acupuncture Treatment for Macular Degeneration: Clinically Proven Methods to Recover & Preserve Retinal Health
by L., Dr. Andy Rosenfarb ND (Author)
For over two decades, Dr. Andy Rosenfarb has been helping patient with Macular Degeneration patients recover and preserve their vision. He is the worlds leading authority on Chinese Medicine and Acupuncture for Macular Degeneration. In his book, Dr. Rosenfarb answers readers’ questions about using acupuncture for Macular Degeneration. • How does acupuncture actually work to increase vision? SEE PAGE 3. • How many sessions before results can be seen? SEE PAGE 6. • If you are thinking of being treated more often, SEE PAGE 12 before you do. • Should your conventional eye doctor... View Details
The First Year: Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed
by Daniel L. Roberts (Author)
Age-related macular degeneration (AMD) is a progressive disease of the retina wherein the light-sensing cells in the central area of vision (the macula) stop working and eventually die. AMD is the leading cause of legal blindness in people over 50. From the moment of his own diagnosis, educator and musician Dan Roberts has made it his mission to provide the most up-to-date information about AMD, its effects and challenges, through his website at mdsupport.org. Receiving over 60,000 unique visitors monthly, MD Support is the go-to for all things AMD. Now, as a "patient-expert," Roberts applies... View Details
Macular Degeneration: A Complete Guide for Patients and Their Families
by Michael A. Samuel (Author)
For people who start losing their vision to macular degeneration, the prospect of impending blindness is frightening and terribly depressing. They often get contradictory advice about surgery, medical treatments, natural supplements, and lifestyle changes that might arrest or reverse the condition, and these conflicting recommendations only compound their anxiety.
Finally, in Macular Degeneration: A Complete Guide for Patients and Their Families, patients and their loved ones can turn to one easy-to-understand and authoritative source for up-to-date information about... View Details
Macular Degeneration: From Diagnosis to Treatment
by David S. Boyer MD (Author), Homayoun Tabandeh MD (Author)
With a focus on giving those diagnosed with macular degeneration the necessary information to make sound treatment choices, this reference aims to answer patients’ questions and ease their anxiety. The book provides information on the symptoms, causes, and emotional impact of macular degeneration; how the disease is diagnosed; choosing the right physician; and how to adapt the home and workplace to be “eye friendly.” In addition, it outlines the newest treatment options, drugs and surgical techniques, ways to slow the progression of the... View Details